*When a postdoctoral fellow prepared to return to his home country a few years ago, I asked him why he was reluctant to submit his work to* Molecular Therapy. *After some hesitation, he admitted that it was because the impact factor of the new journal was not yet known. Apparently, to get an appointment or promotion in rank in his nation\'s universities required that he submit all of his publications, which were then each multiplied by the impact factor of the journal in which they were published. The sum total of these impact factors determined the rank of the applicant---much like a score in an Olympic event. This approach is becoming a common practice. Sadly, it neglects the fact that while leading journals like* Science *and* Nature *are generally thought to only publish high impact papers, good and important science is published in many outstanding scientific journals.*

What is an impact factor? It is a measure of how often a scientific paper is cited, with the underlying assumption that a more highly cited paper is also more highly read. In reality, citations are often just copied from the reference list of one paper to another. Therefore a largely unremarkable or insignificant paper rarely read by anyone other than the authors can end up being highly cited. Last year, two researchers at the University of California Los Angeles tracked identical errors in reference lists originating from a seminal paper published in a physics journal and concluded that nearly 80% of the authors citing the reference had not read the paper in question. Unfortunately, I suspect this probably holds true for biological journals as well.

Are citations, and therefore impact factors, surrogates for quality? Do they really matter? They clearly do---because candidates for appointments, promotions, and grants are judged on the quality of their publications and, more importantly, the journals in which they are published. The underlying assumption is that publications in high profile (impact) journals must be important and significant. Few reviewers have the time to read a candidate\'s publication portfolio, and instead one assumes that a paper published in a high profile journal has gone through a rigorous process of scientific peer review. There is no doubt that exciting science is often published in high profile journals, but good (sometimes pejo ratively called "solid") science is also published in specialty journals that serve the different scientific communities. The work cited in the Nobel Prize citation of Sir John Sulston was published in *Genetics,* as was much of the early work on yeast genetics by Nobel Laureate Lee Hartwell. The original work describing the discovery of ubiquitin and its role in protein degradation was published in the *Journal of Biological Chemistry.*

Impact factors clearly have a role to play; however, it appears that they have assumed a disproportionate significance in our current scientific culture. Good science is good science, regardless of where it is published. Bad science will eventually fall out of favor, regardless of where it was published. Every author wants to see his or her work widely read and quot ed. The high impact scientific journals try to publish what is topical. It is unlikely that just a year ago the complete sequence of a corona virus genome would have been published as an article in *Science,* but SARS changed all that. Impact factors are here to stay and *Molecular Therapy\'s* impact will continue to climb (currently, we rank a 5.64). More importantly, how ever, we will continue to provide rigorous, fair and speedy reviews of papers submitted to the journal, and will continue to publish only the best work in the field of molecular and cellular therapy. I would nevertheless like to inject a note of caution that we should not exaggerate the importance of impact factors. Good science---like good wine---will age well!
